Evofem Biosciences (EVFM) Competitors $0.0092 +0.00 (+2.22%) As of 02/21/2025 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrends EVFM vs. ATNF, SNPX, CPHI, PPBT, SNOA, ALBT, AWH, ARTL, GNPX, and THARShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include 180 Life Sciences (ATNF), Synaptogenix (SNPX), China Pharma (CPHI), Purple Biotech (PPBT), Sonoma Pharmaceuticals (SNOA), Avalon GloboCare (ALBT), Aspira Women's Health (AWH), Artelo Biosciences (ARTL), Genprex (GNPX), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. 180 Life Sciences Synaptogenix China Pharma Purple Biotech Sonoma Pharmaceuticals Avalon GloboCare Aspira Women's Health Artelo Biosciences Genprex Tharimmune Evofem Biosciences (NASDAQ:EVFM) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Does the MarketBeat Community favor EVFM or ATNF? Evofem Biosciences received 260 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 28.57% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperformEvofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% 180 Life SciencesOutperform Votes228.57% Underperform Votes571.43% Do institutionals & insiders have more ownership in EVFM or ATNF? 0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by company insiders. Comparatively, 0.2% of 180 Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is EVFM or ATNF more profitable? 180 Life Sciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences-46.42% -91.97% -61.93% 180 Life Sciences N/A -558.93%-54.10% Which has more volatility and risk, EVFM or ATNF? Evofem Biosciences has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Does the media prefer EVFM or ATNF? In the previous week, 180 Life Sciences had 2 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for 180 Life Sciences and 0 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score. Company Overall Sentiment Evofem Biosciences Neutral 180 Life Sciences Neutral Which has stronger valuation & earnings, EVFM or ATNF? Evofem Biosciences has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$18.22M0.06$52.98M-$0.62-0.01180 Life SciencesN/AN/A-$19.93MN/AN/A SummaryEvofem Biosciences beats 180 Life Sciences on 6 of the 11 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$7.05B$5.80B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.016.1126.4518.81Price / Sales0.06313.84450.0676.66Price / CashN/A67.8344.0437.47Price / Book0.006.747.634.64Net Income$52.98M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.04%-1.85%-2.63%1 Month PerformanceN/A-1.57%0.19%-2.37%1 Year PerformanceN/A-3.19%17.21%13.64% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem BiosciencesN/A$0.01+2.2%N/A-65.9%$1.04M$18.22M-0.01120High Trading VolumeATNF180 Life SciencesN/A$1.33-2.2%N/A-65.6%$4.23MN/A0.007Analyst ForecastNews CoveragePositive NewsSNPXSynaptogenix1.9617 of 5 stars$3.10+6.9%$14.00+351.6%-55.4%$4.20MN/A0.004Gap UpCPHIChina PharmaN/A$0.22+1.9%N/A-58.1%$4.16M$7.01M0.00250Analyst ForecastNews CoveragePPBTPurple Biotech2.4514 of 5 stars$3.10-2.8%$33.00+964.5%N/A$4.12MN/A-0.3520Gap DownSNOASonoma Pharmaceuticals0.201 of 5 stars$2.49-5.0%N/A+1,447.9%$4.03M$12.73M-0.62180Negative NewsALBTAvalon GloboCare1.0183 of 5 stars$3.69-0.8%N/A-7.4%$4.02M$1.26M-0.185News CoverageGap DownAWHAspira Women's Health1.0926 of 5 stars$0.24-14.3%$4.40+1,733.3%-95.3%$4.00M$9.15M-0.20110Gap UpHigh Trading VolumeARTLArtelo Biosciences3.1843 of 5 stars$1.19-14.4%$5.50+362.2%-27.5%$3.84MN/A-0.415News CoverageGap DownHigh Trading VolumeGNPXGenprex4.4819 of 5 stars$0.44-6.4%$10.00+2,168.1%-91.2%$3.75MN/A0.0020Gap DownHigh Trading VolumeTHARTharimmune2.22 of 5 stars$1.90flat$17.00+794.7%-66.2%$3.67MN/A0.002Upcoming EarningsNews Coverage Related Companies and Tools Related Companies 180 Life Sciences Alternatives Synaptogenix Alternatives China Pharma Alternatives Purple Biotech Alternatives Sonoma Pharmaceuticals Alternatives Avalon GloboCare Alternatives Aspira Women's Health Alternatives Artelo Biosciences Alternatives Genprex Alternatives Tharimmune Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVFM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
